{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T04:50:25Z","timestamp":1772081425630,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,11,10]],"date-time":"2017-11-10T00:00:00Z","timestamp":1510272000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.clml.2017.10.004","type":"journal-article","created":{"date-parts":[[2017,10,14]],"date-time":"2017-10-14T03:17:21Z","timestamp":1507951041000},"page":"13-25.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["A Systematic Review of Treatments of Relapsed\/Refractory Mantle Cell Lymphoma"],"prefix":"10.1016","volume":"18","author":[{"given":"Madeliene","family":"Parrott","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Rule","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0005-3079","authenticated-orcid":false,"given":"Michael","family":"Kelleher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jayne","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2017.10.004_bib1","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","article-title":"The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications","volume":"117","author":"Campo","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.10.004_bib2","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/bjh.12046","article-title":"Guidelines for the investigation and management of mantle cell lymphoma","volume":"159","author":"McKay","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2017.10.004_bib4","doi-asserted-by":"crossref","first-page":"iv62","DOI":"10.1093\/annonc\/mdx223","article-title":"Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow up","volume":"28","author":"Dreyling","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2017.10.004_bib5","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","article-title":"Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001","volume":"107","author":"Morton","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.10.004_bib6","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.10.004_bib7","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood-2014-05-521898","article-title":"Mantle cell lymphoma: evolving management strategies","volume":"125","author":"Campo","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.10.004_bib8","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1038\/sj.leu.2402272","article-title":"Blastic variant of mantle cell lymphoma: a rare but highly aggressive subtype","volume":"15","author":"Bernard","year":"2001","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.10.004_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clml.2014.03.006","article-title":"Clinical efficacy and safety in relapsed\/refractory mantle cell lymphoma: a systematic literature review","volume":"15","author":"Njue","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2017.10.004_bib11","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1200920","article-title":"Treatment of older patients with mantle cell lymphoma","volume":"376","author":"Kluin-Nelemans","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.10.004_bib12","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1038\/leu.2014.171","article-title":"How to manage mantle cell lymphoma","volume":"28","author":"Dreyling","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.10.004_bib14","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1093\/oxfordjournals.annonc.a058904","article-title":"Report of the workshop on mantle cell lymphoma (MCL)","volume":"5","year":"1994","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2017.10.004_bib15","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0140-6736(15)00667-4","article-title":"Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle cell lymphoma: an international, randomised, open-label, phase 3 trial","volume":"387","author":"Dreyling","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2017.10.004_bib16","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","volume":"104","author":"Forstpointner","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.10.004_bib17","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1182\/blood-2006-04-016725","volume":"108","author":"Forstpointner","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.10.004_bib18","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/bjh.13101","article-title":"Addition of bortezomib to standard dose chop chemotherapy improves response and survival in relapsed mantle cell lymphoma","volume":"168","author":"Furtado","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2017.10.004_bib19","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","article-title":"Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma","volume":"27","author":"Hess","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.10.004_bib20","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(15)00447-7","article-title":"Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial","volume":"17","author":"Rummel","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2017.10.004_bib21","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1470-2045(15)00559-8","article-title":"Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicenter trial","volume":"17","author":"Trneny","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2017.10.004_bib22","unstructured":"Higgins JPT, Green S (eds). Cochrane Handbook for Systematic Reviews of Interventions, version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available at: www.cochrane-handbook.org. Accessed: December 27, 2016."},{"key":"10.1016\/j.clml.2017.10.004_bib23","doi-asserted-by":"crossref","unstructured":"Jerkeman M, Hutchings M, Raty R, et\u00a0al. Ibrutinib-lenalidomide-rituximab in patients with relapsed\/refractory mantle cell lymphoma: first results from the Nordic Lymphoma Group MCL6 (PHILEMON) phase II trial. Presented at the 58th Annual Meeting of the American Society of Hematology; December 3-6, 2016, San Diego, CA.","DOI":"10.1182\/blood.V128.22.148.148"},{"key":"10.1016\/j.clml.2017.10.004_bib24","doi-asserted-by":"crossref","unstructured":"Andorsky DJ, Yacoub A, Bitran J, et\u00a0al. MAGNIFY: phase IIIb randomized study of lenalidomide plus rituximab (R2) followed by lenalidomide vs. rituximab maintenance in subjects with relapsed\/refractory follicular, marginal zone, or mantle cell lymphoma. Presented at the 58th Annual Meeting of the American Society of Hematology, December 3-6, 2016, San Diego, CA.","DOI":"10.1182\/blood.V128.22.1798.1798"},{"key":"10.1016\/j.clml.2017.10.004_bib25","unstructured":"Kumar A, Guillen-Rodriguez J, Schatz JH, et\u00a0al. A phase II, open-label study of bortezomib (Velcade\u00ae), cladribine, and rituximab (VCR) in advanced, newly diagnosed and relapsed\/refractory mantle cell and indolent lymphomas. Presented at the 58th Annual Meeting of the American Society of Hematology, December 3-6, 2016, San Diego, CA."},{"key":"10.1016\/j.clml.2017.10.004_bib26","unstructured":"Morschhauser F, Cartron G, Salles GA, et\u00a0al. A phase II LYSA study of obinutuzumab combined with lenalidomide for relapsed or refractory aggressive B-cell lymphoma. Presented at the 58th Annual Meeting of the American Society of Hematology, December 3-6, 2016, San Diego, CA."},{"key":"10.1016\/j.clml.2017.10.004_bib27","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.10.004_bib28","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","article-title":"Multicentre phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma","volume":"24","author":"Fisher","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.10.004_bib29","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.10.004_bib30","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1200\/JCO.2013.49.2835","article-title":"Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study","volume":"31","author":"Goy","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.10.004_bib31","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3324\/haematol.2015.128710","article-title":"The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomised UK National Cancer Research Institute Trial","volume":"101","author":"Rule","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2017.10.004_bib32","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1080\/10428190802357071","article-title":"The NF-\u03baB inhibitors (bortezomib and DHMEQ) sensitise rituximab-resistant AIDS-B-non-Hodgkin lymphoma to apoptosis by various chemotherapeutic drugs","volume":"49","author":"Vega","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2017.10.004_bib33","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardise response criteria for non-Hodgkin's lymphoma. NCI Sponsored International Working Group","volume":"17","author":"Cheson","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.10.004_bib34","doi-asserted-by":"crossref","unstructured":"Rule S, Dreyling M, Hess G, et\u00a0al. Overall survival outcomes in patients with mantle-cell lymphoma treated with ibrutinib: a pooled analysis of 370 patients from 3 international open-label studies. Presented at the 21st Congress of the European Haematology Association, June 9-12, 2016, Copenhagen, Denmark.","DOI":"10.1111\/bjh.14870"},{"issue":"suppl","key":"10.1016\/j.clml.2017.10.004_bib35","volume":"34","author":"Rummel","year":"2016","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265017308194?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265017308194?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:30:27Z","timestamp":1761870627000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265017308194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S2152265017308194"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2017.10.004","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Systematic Review of Treatments of Relapsed\/Refractory Mantle Cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2017.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}